Bio-Rad Q2 Revenue Beats by $27M on Diagnostics Strength, Reaffirms Outlook
BIO sits 38% above its 52-week low of $236.73.
Summary
Bio-Rad posted Q2 revenue of $651M, beating the $623.99M consensus by over 4%, driven by clinical diagnostics growth including a 20%+ surge in digital PCR instruments. EPS came in at $13.85 with net income of $371.4M and gross margin of 53.1%. The company reaffirmed its 2026 non-GAAP revenue outlook of -3% to +0.5% and operating margin of 10-12%, signaling stability despite life science segment weakness from academic market challenges. This follows activist pressure from Elliott Management reported in May, adding weight to the operational improvements. The beat and reaffirmed guidance provide a positive catalyst, though the stock already trades near its 52-week high and above the median analyst target of $310.
At the time of this announcement, BIO was trading at $326.33 on NYSE in the Life Sciences sector, with a market capitalization of approximately $8.9B. The 52-week trading range was $236.73 to $343.12. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.